Search Results

Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT 1A agonist activity, for the treatment of generalized anxiety disorder (GAD).

Sunovion Pharmaceuticals Inc. announced that the Company’s patient support program, Sunovion Answers, has been named as a J.D. Power 2022 Certified Customer Service Program℠.

Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the first patient has been enrolled in a Phase 2/3 clinical study to evaluate ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, as an adjunctive therapy in the treatment of adults living with major depressive disorder (MDD).

Nika Pharmaceuticals, Inc. introduces its plans to develop the company into a sustainable business project that will consistently grow, bring good profits and provide dividends to its shareholders.